Company: SMNR
Filing Date: 2025-10-21
Form Type: S-1
Source: 0001193125-25-245178
Chunk: 7

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-10-21
Form: S-1
Chunk 7
---
 “should,” “would” and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on information available as of the date of this prospectus and our management’s current expectations, forecasts and assumptions, and involve a number of judgments, known and unknown risks, uncertainties or other assumptions and other factors, many of which are outside the control of the Company and our directors, officers and affiliates, that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in this prospectus. There can be no assurance that future developments will be those that have been anticipated. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in “ Risk Factors,” those discussed and identified in public filings made with the SEC by Semnur and the following:

| • |     | the ability to obtain the listing of our Common Stock on Nasdaq; |

| • |     | our public securities’ liquidity and trading; |

| • |     | our ability to raise financing in the future; |

| • |     | our expected use of proceeds from future issuances of equity or convertible debt securities; |

| • |     | our future financial performance, including our revenue, costs of revenue and operating expenses; |

| • |     | our future use of equity or debt financings to execute our business strategy; |

| • |     | our ability to use cash on hand to meet current and future financial obligations, including funding our operations, debt service requirements and capital expenditures; |

| • |     | the outcome of any legal proceedings that may be instituted against us; |

| • |     | our ability to attract and retain qualified directors, officers, employees and key personnel; |

| • |     | our ability to compete effectively in a highly competitive market; |

| • |     | the competition from larger biotechnology companies that have greater resources, technology, relationships and/or expertise; |

| • |     | the ability to protect and enhance our corporate reputation and brand; |

| • |     | the impact from